Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1537 Antitumor Efficacy of Temozolomide in Patients with Metastatic Pulmonary Carcinoids

Introduction: Temodal (TMZ) is an oral alternative to dacarbazine.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Bello Roufai D, Planchard D, Walter T, Berdelou A, Guigay J,

Keywords: pulmonary carcinoids, temozolomide, safety,

#1225 Everolimus in Patients (pts) with Advanced Lung Carcinoids: Evaluation of Median Progression Free Survival (PFS) and Median Time to First Dose Decrease or Discontinuation (DDD)

Introduction: Treatment of well-differentiated (WD) lung neuroendocrine tumors (NETs) is challenging. Everolimus (mTOR inhibitor) has shown encouraging results in digestive NETs but data about its activity on lung carcinoid are sparse.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Gianoncelli L, Guigay J, Caramella C, Borget I, Mir O,

Keywords: lung carcinoid, everolimus, mTOR inhibitor,

#1082 Characterization and Prognosis of Patients with Metastatic Lung Carcinoid Tumors

Introduction: Data on metastatic lung carcinoid tumors are limited.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Walter T, Planchard D, Bouledrak K, Guigay J, Dussol A,

Keywords: lung, metastatic, prognosis,

#714 Oxalipatin-Based Chemotherapy for Grade 3 Neuroendocrine Carcinoma after Failure of Platinum- Based Chemotherapy

Introduction: Cisplatin/etoposide regimen is the recommended first line treatment for poorly differentiated grade 3 neuroendocrine carcinoma (G3-NEC). There is no standard second line.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Hadoux J, Guigay J, Malka D, Planchard D, Boige V,

Keywords: neuroendocrine carcinoma, grade 3, oxaliplatin,